التفاصيل البيبلوغرافية
| العنوان: |
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. |
| المؤلفون: |
Cho, S.-H., Shim, H.-J., Lee, S. R., Ahn, J.-S., Yang, D.-H., Kim, Y.-K., Nam, T. K., Lee, J.-J., Kim, H.-J., Chung, I.-J. |
| المصدر: |
Diseases of the Esophagus; Nov2008, Vol. 21 Issue 8, p697-703, 7p, 4 Charts, 1 Graph |
| مصطلحات موضوعية: |
ESOPHAGEAL cancer, DRUG therapy, CISPLATIN, SQUAMOUS cell carcinoma, NEUTROPENIA |
| مستخلص: |
How best to manage advanced esophageal cancer remains unresolved, especially in palliative care. Here, in a pilot study, we evaluated the efficacy and safety of concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Patients with locally advanced or metastatic squamous cell carcinoma of the esophagus received S-1 and cisplatin at doses of 70 mg/m2/day for 14 days and 70 mg/m2 on day 1, respectively, every 3 weeks. Concurrently, radiotherapy was started at a dose of 200 cGy/day, up to a total of 5400 cGy. After concurrent chemoradiotherapy, additive chemotherapy was repeated up to six cycles. Thirty patients were enrolled in this study; of the 27 in whom efficacy could be evaluated, an objective response rate was seen in 20 (74.1%), including five (18.5%) complete pathologic responses in primary lesions. Improvement of dysphagia was seen in 21 (76%) patients. In patients with stage II or III esophageal cancer, the median progression-free survival and overall survival were 10.6 ± 0.6 months (95% CI: 9.4–11.8) and 23.0 ± 5.1 months (95% CI: 13.0–32.9), respectively. In patients with stage IV esophageal cancer, the median progression-free survival and overall survival were 5.4 ± 1.6 months (95% CI: 2.2–8.6) and 11.6 ± 1.6 months (95% CI: 8.4–14.8), respectively. The main hematological toxicity was neutropenia, but no neutropenic fever was observed. The major non-hematological toxicities were asthenia and vomiting, mostly of grades 1 and 2. Thus, concurrent chemoradiotherapy with S-1 and cisplatin may be a promising nonsurgical treatment in advanced esophageal cancer. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diseases of the Esophagus is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
